首页 产品目录 全部产品 (4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,43S,49S,52R)-52-((5S,8S,11S)-14-amino-5-(4-aminobutyl)-8-(hydroxymethyl)-11-isobutyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazatetradecanamido)-40-(4-aminobutyl)-49-benzyl-28-((S)-sec-butyl)-34-(carboxymethyl)-31-(3-guanidinopropyl)-16,22-bis(hydroxymethyl)-10,37,43-triisobutyl-19-(2-(methylthio)ethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecaazacyclotripentacontane-4-carboxylic acid

(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,43S,49S,52R)-52-((5S,8S,11S)-14-amino-5-(4-aminobutyl)-8-(hydroxymethyl)-11-isobutyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazatetradecanamido)-40-(4-aminobutyl)-49-benzyl-28-((S)-sec-butyl)-34-(carboxymethyl)-31-(3-guanidinopropyl)-16,22-bis(hydroxymethyl)-10,37,43-triisobutyl-19-(2-(methylthio)ethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecaazacyclotripentacontane-4-carboxylic acid

(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,43S,49S,52R)-52-((5S,8S,11S)-14-amino-5-(4-aminobutyl)-8-(hydroxymethyl)-11-isobutyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazatetradecanamido)-40-(4-aminobutyl)-49-benzyl-28-((S)-sec-butyl)-34-(carboxymethyl)-31-(3-guanidinopropyl)-16,22-bis(hydroxymethyl)-10,37,43-triisobutyl-19-(2-(methylthio)ethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecaazacyclotripentacontane-4-carboxylic acid

产品编号 :
Cas No. :
包装规格 纯度 目录价 会员专享价 库存 数量

抱歉,暂无牌价信息

晶智化学产品均仅供科研使用。在任何情况下,我们均不提供用于动物或人体用途的产品或服务。

基础信息

CAS No.

127869-51-6

英文名称

(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,43S,49S,52R)-52-((5S,8S,11S)-14-amino-5-(4-aminobutyl)-8-(hydroxymethyl)-11-isobutyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazatetradecanamido)-40-(4-aminobutyl)-49-benzyl-28-((S)-sec-butyl)-34-(carboxymethyl)-31-(3-guanidinopropyl)-16,22-bis(hydroxymethyl)-10,37,43-triisobutyl-19-(2-(methylthio)ethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecaazacyclotripentacontane-4-carboxylic acid

别名

NATRIURETIC PEPTIDE, C-TYPE, HUMAN AND PORCINE;GLY-LEU-SER-LYS-GLY-CYS-PHE-GLY-LEU-LYS-LEU-ASP-ARG-ILE-GLY-SER-MET-SER-GLY-LEU-GLY-CYS;GLSKGCFGLKLDRIGSMSGLGC;GLSKGCFGLKLDRIGSMSGLGC (DISULFIDE BRIDGE: 6-22);H-GLY-LEU-SER-LYS-GLY-CYS-PHE-GLY-LEU-LYS-LEU-ASP-ARG-ILE-GLY-SER-MET-SER-GLY-LEU-GLY-CYS-OH;H-GLY-LEU-SER-LYS-GLY-CYS-PHE-GLY-LEU-LYS-LEU-ASP-ARG-ILE-GLY-SER-MET-SER-GLY-LEU-GLY-CYS-OH (DISULFIDE BRIDGE: 6-22);CNP;CNP-22, HUMAN

标准英文名

(4R,10S,16S,19S,22S,28S,31S,34S,37S,40S,43S,49S,52R)-52-((5S,8S,11S)-14-amino-5-(4-aminobutyl)-8-(hydroxymethyl)-11-isobutyl-4,7,10,13-tetraoxo-3,6,9,12-tetraazatetradecanamido)-40-(4-aminobutyl)-49-benzyl-28-((S)-sec-butyl)-34-(carboxymethyl)-31-(3-guanidinopropyl)-16,22-bis(hydroxymethyl)-10,37,43-triisobutyl-19-(2-(methylthio)ethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecaazacyclotripentacontane-4-carboxylic acid

分子式

C93H157N27O28S3

分子量

2197.64

精确分子量

2196.09

SMILES

CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CN)CSSC[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)CNC1=O

标准SMILES

C[C@@H](CC)[C@@H]1NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC2C=CC=CC=2)NC(=O)[C@H](CSSC[C@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CN

用途

C-type natriuretic peptide (CNP) is a member of the natriuretic peptide family involved in the regulation of fluid-electrolyte balance and vascular tone; it is present in the central nervous system of mammals and participates in the regulation of fluid and electrolyte homeostasis, blood pressure, learning, and memory; intracerebroventricular (i.c.v.) administration of CNP (1-22) at a dose of 2 nmol enhances the severity of picrotoxin-kindled convulsions 24 and 48 hours after peptide application.

InChIKey

UHSBKBYWHCBDCJ-DYGWFTAGSA-N

安全信息

SureRoute逆合成路线

1.  127869-51-6 逆合成路线 1

—
—
ACHOXA920
127869-51-6
来源: SureRoute

2.  127869-51-6 逆合成路线 2

—
—
ACHOXA920
127869-51-6
来源: SureRoute

3.  127869-51-6 逆合成路线 3

—
—
ACHOXA920
127869-51-6
来源: SureRoute
评论 0
我是晶智Agent,
您的化学小助手